COLL in the 13F filings
Collegium Pharmaceutical Inc · CUSIP 19459J104
- Quarter end
- 30 Sep 2023
- the date the book describes
- Filed
- 14 Nov 2023
- latest of these filings; the earliest 14 Nov 2023
- Managers listing it
- 1
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q2 2023 and Q3 2023; 0 listed it in both
- Shares listed
- 1,172,598
- combined, among listed positions
- Reported value
- $26m
- combined, at the quarter end
Managers listing COLL in Q3 2023
1 of 1 holder
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | 1,172,598 | $26m | under 0.1% | Trimmed | n.a. | 14 Nov 2023 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
No increase among listed positions.
Reductions
No reduction among listed positions.
New positions and exits
New (0)
No new position among listed positions.
Exited (1)
- Maverick Capital Ltdwas $224k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2016 | 1 | $282k | n.a. | n.a. |
| Q3 2016 | 1 | $458k | n.a. | n.a. |
| Q4 2016 | 1 | $1.9m | n.a. | n.a. |
| Q1 2017 | 1 | $1.0m | n.a. | n.a. |
| Q2 2017 | 2 | $1.5m | n.a. | n.a. |
| Q3 2017 | 1 | $525k | n.a. | n.a. |
| Q4 2017 | 2 | $64m | n.a. | n.a. |
| Q1 2018 | 2 | $99m | n.a. | n.a. |
| Q2 2018 | 3 | $102m | n.a. | n.a. |
| Q3 2018 | 2 | $9.3m | n.a. | n.a. |
| Q4 2018 | 2 | $74m | n.a. | n.a. |
| Q1 2019 | 1 | $6.0m | n.a. | n.a. |
| Q2 2019 | 1 | $721k | n.a. | n.a. |
| Q3 2019 | 1 | $502k | n.a. | n.a. |
| Q4 2019 | 3 | $99m | n.a. | n.a. |
| Q1 2020 | 2 | $90m | n.a. | n.a. |
| Q2 2020 | 2 | $93m | n.a. | n.a. |
| Q3 2020 | 2 | $110m | n.a. | n.a. |
| Q4 2020 | 2 | $103m | n.a. | n.a. |
| Q1 2021 | 2 | $98m | n.a. | n.a. |
| Q2 2021 | 3 | $99m | n.a. | n.a. |
| Q3 2021 | 1 | $81m | n.a. | n.a. |
| Q4 2021 | 2 | $71m | n.a. | n.a. |
| Q1 2022 | 1 | $1.1m | n.a. | n.a. |
| Q2 2022 | 2 | $40m | n.a. | n.a. |
| Q3 2022 | 3 | $32m | n.a. | n.a. |
| Q4 2022 | 3 | $35m | n.a. | n.a. |
| Q1 2023 | 2 | $31m | n.a. | n.a. |
| Q2 2023 | 1 | $224k | n.a. | n.a. |
| Q3 2023 | 1 | $26m | n.a. | n.a. |
| Q4 2023 | 1 | $43m | 1 | 0 |
| Q1 2024 | 4 | $59m | 4 | 0 |
| Q2 2024 | 3 | $52m | 3 | 0 |
| Q3 2024 | 2 | $67m | 2 | 1 |
| Q4 2024 | 2 | $48m | 1 | 1 |
| Q1 2025 | 2 | $54m | 1 | 1 |
| Q2 2025 | 1 | $45m | 0 | 1 |
| Q3 2025 | 5 | $60m | 4 | 0 |
| Q4 2025 | 6 | $209m | 18 | 14 |
| Q1 2026 | 5 | $157m | 16 | 15 |
| Q2 2026 | 4 | $180m | 11 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
COLL and LLY →COLL and JNJ →COLL and VRTX →Choose a stock to compare with COLL →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own COLL, latest filings →Back to the 13F Explorer →